Health technology assessments (HTAs) rely on comparative evidence about new treatments and competing therapies, which are typically derived using indirect or mixed treatment comparisons (ITC/MTCs). These are not always feasible or appropriate, particularly in rapidly evolving therapeutic areas, like oncology. For instance, some comparisons may not be possible due to incomplete evidence networks; or, heterogeneity between studies due to differences in design or population may make an MTC inappropriate. There is, therefore, a need for alternative techniques, such as Simulated Treatment Comparisons (STCs). This technique is designed to derive comparisons between treatments after adjustment for differences between the populations of the two studies. This targeted comparison requires individual patient-level data (IPD) for at least one of the treatments (the index), and are appropriate when the trials used for the comparison are sufficiently comparable in design and methods, but differ in the profiles of their population in measured risk factors. The differences can be adjusted analytically using IPD via regression equations. This produces endpoint estimates for the index treatment that reflect the profile of the comparator population. These can then be contrasted with published results for the comparator to obtain a measure of difference between treatments. Since only measured risk factors can be included in the adjustment, the potential for residual confounding remains. Another potential bias is a possible "study effect" whereby other differences between studies distort the comparisons. This can be assessed using the reference groups of the trials, if these received the same treatment. STCs have been used in HTA submissions, and it is likely that its use and that of other alternative techniques will increase particularly in areas with rapid drug development. In the presence of heterogeneity or incomplete evidence networks, STCs can provide comparative evidence where these may be otherwise deemed unavailable due to limitations of ITCs/MTCs.
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RCTs remain the gold standard for evaluation of drug efficacy and safety. However, the only way of identifying treatment pathways and improving understanding of costs and outcomes at different stages of care is via longitudinal observational studies. Observational data from electronic health records (EHRs) are increasingly being used to support pharmaco-epidemiological research. Coverage, data quality and validity of UK EHR databases such as the Clinical Practice Research Datalink (CPRD) have improved in recent years, and many papers confirm the validity of data in diagnoses such as cancer. Published data show that recording of cancer diagnosis and mortality in primary care electronic records is generally consistent with Cancer Registry (CR) data in England. The use of "read codes" in CPRD to identify an event (cancer diagnosis or referral to secondary care) and the possibility of anonymous linkage to secondary care databases (e.g. Hospital Episode Statistics [HES] for information about hospital management as an in-or out-patient, to other CR data, and accurate mortality tracking by the Office for National Statistics [ONS]) allows the data and diagnosis to be validated against multiple sources, as well as identifying treatment pathways in both secondary and primary care. There are some limitations, e.g. not all patients identified in GP practices via the CPRD are linked to other databases. Management data such as secondary care prescribing are difficult to access (not available in HES) but may be available from reviewing anonymized patient notes or by connecting to other datasets. For example, IMS Health links CPRD data with hospital pharmacy audit data and HES data. However these data have only become available recently, are expensive to access and currently patient population coverage is low. We will provide a detailed description of the possibilities for integrated database use to map treatment pathways for cancer patients.
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Single technology appraisals (STAs) are a key component of the development of NICE technology appraisals guidance, but are a time and resource intensive process. Societal costs are incurred during STAs by holding the NICE Appraisal Committee, via payment to the evidence review group (ERG) and in the opportunity costs of other technologies which are not appraised. In addition, the drug manufacturer also incurs substantial costs in preparation of their submission and throughout the STA process. Recently aripiprazole, an atypical antipsychotic drug for the treatment of manic episodes in adolescent bipolar I disorder, was subjected to an STA and received positive guidance. It was apparent to the ERG from the outset of the appraisal that the conclusion would be positive as: the drug had a small acquisition cost; was already in widespread use; would shortly be going generic; and had a profile similar to its comparators. As the budget impact over a 5-year period estimated by the manufacturer was less than the payment received by the ERG, it was unlikely that the STA represented efficient use of resources. Given a fundamental role of NICE is in assessing cost-effectiveness, the option of un-referring STAs in rare circumstances has appeal. It is proposed that if certain criteria are met then it would be more cost-effective to not proceed with an STA. These include: small patient population, commonly used in current clinical practice, patent expiring in Systematic reviews aim to identify, select, synthesize and appraise all high quality research evidence relevant to a particular research question, and are widely accepted as the gold standard for providing the best evidence for use in decision making. They are essential, routine components of submission data packages for health technology assessments (HTAs) of products undergoing evaluation for reimbursement and market access. Additionally, systematic reviews are often the source for clinical evidence used in health economic modelling to evaluate cost-effectiveness. Thus, they represent a substantial investment of resources, and incorrect or incomplete reviews could invalidate the proposed clinical and economic value of a product set out in a health technology submission and result in unfavourable reimbursement decisions and/or delayed market access. There are a number of best practice criteria set down for systematic reviews; the most widely recognised being from the Cochrane group. However, when carrying out a systematic review for HTA purposes researchers should be aware of the additional requirements set out by each agency. The Cochrane, UK National Institute for Clinical Excellence (NICE) and Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWIG) methodological guidelines for conducting and reporting systematic reviews were analysed and an 'inclusive' checklist of requirements was developed to ensure the systematic review and meta-analysis met the broad set of HTA requirements and minimise the risk of having to repeat the procedure or create the need for a HTA review group to carry out its own review, which could potentially lead to an unfavourable reimbursement decision or a restriction on use. An awareness of specific HTA systematic review requirements can help optimise the preparation of a data package for HTA submission and hence maximise the chances of success. Objectives: The model aims to determine the optimal allocation of financial resources amongst various paediatric vaccines accounting for changes in budget and availability of new vaccines over time. This approach aims to inform decision makers who are seeking to extend their national immunisation programmes about the optimal mix of vaccines and sequence of their introduction, meanwhile accounting for their preferences in clinical and cost outcomes. MethOds: An MCD optimisation model was developed in Microsoft Excel that considered availability of new vaccines and budget changes over time, optimal mix of vaccines in previous years, budget investment time horizon, cumulative outcomes time horizon, maximal achievable vaccination coverage, specific target populations. The optimal mix of vaccines within an available portfolio was determined by manually programmed linear optimisation based on a defined objective function and budget constraints. The objective function includes maximisation of prevention of disease cases, GP visits, hospitalisations, deaths, and cost savings in disease management. A multi-criteria approach allows for redistributing weights across clinical and cost outcomes in the objective function. Vaccination against rotavirus, varicella, influenza and pneumococcal disease was evaluated, based on disease incidences and direct medical costs from Poland. Relative risk reductions induced by vaccination were based on randomised controlled trials and post-marketing surveillance data. Results: Dependent on the definition of objective function, the allocation of budget across a portfolio of vaccines resulted in different recommendations. If deaths-avoided was weighted at maximum, pneumococcal vaccine was ranked first, followed by rotavirus and influenza vaccination. If cost savings received the maximum preference, vaccination against influenza was ranked first, rotavirus second, pneumococcal third, and varicella fourth. The use of a weighted objective function resulted in different vaccines introduction sequences. cOnclusiOns: The use of an MCD optimisation model provides a tool to inform decision makers about the optimal allocation of financial resources over time. With the rapid pervasion of internet technologies, demand for making health economic evidence, such as mathematical models, accessible through the web increases. Long running computations such as Monte Carlo simulation can impair user experience because of longer waiting time. Our aim is to employ mathematical techniques to reduce the computation time of probabilistic cost effectiveness Monte Carlo models, thus increasing their acceptance when used on the web. We employ the variance reduction technique to reduce computation time while obtaining outcomes with the same Monte Carlo error. The control variate approach is applied. It utilizes information about errors in estimates of known mean Net Monetary Benefit (NMB) quantities to reduce errors in estimation of the cost-effectiveness acceptability curve. The NMB mean value is calculated based on the deterministic counterpart of the model. The said technique has been applied to the published probabilistic decision tree-based Excel model for evaluating cost-effectiveness of breast cancer screening. In this model, different types of probability distributions can be chosen to model uncertainty of disease incidence, mortality rate and intervention effectiveness. By applying the control variate approach we were able to achieve outcome with the same error while performing 50% less simulations as compared to the plain Monte Carlo method. Such performance improvement is yet another step towards increasing user acceptance of web based health economic models with Monte Carlo simulations.
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